Zomedica Corp (AMEX: ZOM) on Tuesday, plunged -0.41% from the previous trading day, before settling in for the closing price of $0.12. Within the past 52 weeks, ZOM’s price has moved between $0.12 and $0.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 97.76% over the past five years. The company achieved an average annual earnings per share of -37.14%. With a float of $962.66 million, this company’s outstanding shares have now reached $979.95 million.
Let’s look at the performance matrix of the company that is accounted for 144 employees. In terms of profitability, gross margin is 55.24%, operating margin of -143.14%, and the pretax margin is -232.24%.
Zomedica Corp (ZOM) Insider Updates
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of Zomedica Corp is 1.76%, while institutional ownership is 9.35%. The most recent insider transaction that took place on Nov 08 ’24, was worth 18,450. In this transaction COO of this company bought 150,000 shares at a rate of $0.12, taking the stock ownership to the 400,000 shares. Before that another transaction happened on Nov 11 ’24, when Company’s Director bought 100,000 for $0.12, making the entire transaction worth $12,100. This insider now owns 2,425,000 shares in total.
Zomedica Corp (ZOM) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -37.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.29% during the next five years compared to 27.70% growth over the previous five years of trading.
Zomedica Corp (AMEX: ZOM) Trading Performance Indicators
Zomedica Corp (ZOM) is currently performing well based on its current performance indicators. A quick ratio of 10.15 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.41.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.06, a number that is poised to hit -0.01 in the next quarter and is forecasted to reach -0.03 in one year’s time.
Technical Analysis of Zomedica Corp (ZOM)
Zomedica Corp (AMEX: ZOM) saw its 5-day average volume 3.6 million, a negative change from its year-to-date volume of 5.79 million. As of the previous 9 days, the stock’s Stochastic %D was 18.47%. Additionally, its Average True Range was 0.00.
During the past 100 days, Zomedica Corp’s (ZOM) raw stochastic average was set at 7.80%, which indicates a significant increase from 6.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 14.21% in the past 14 days, which was lower than the 47.76% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.1250, while its 200-day Moving Average is $0.1370. Nevertheless, the first resistance level for the watch stands at $0.1214 in the near term. At $0.1226, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.1233. If the price goes on to break the first support level at $0.1195, it is likely to go to the next support level at $0.1188. Assuming the price breaks the second support level, the third support level stands at $0.1176.
Zomedica Corp (AMEX: ZOM) Key Stats
Market capitalization of the company is 117.79 million based on 979,950K outstanding shares. Right now, sales total 25,190 K and income totals -34,530 K. The company made 7,000 K in profit during its latest quarter, and -6,700 K in sales during its previous quarter.
